5f cobra catheter

DEB-TACE procedure was conducted under local anesthesia and fluoroscopy. A 5F Cobra catheter (Terumo, Japan) was introduced via the right femoral artery access. Esophageal arteriography was performed to look for tumor staining and its tumor-feeding artery. A 2.4-Fr microcatheter was selectively catheterized into the tumor-feeding artery, and then DEB-TAE was performed (Figs.1d, e, 2c, d,3b, c, 4d). Raltitrexed of 4mg or oxaliplatin of 100mg were transcatheter infused before CalliSpheres beads embolization. Doxorubicin (60mg) was loaded with CalliSpheres beads (300500m, Jiangsu Hengrui Medicine Co. Ltd., Nanjing, China) for about half an hour. Final arteriography was performed to confirm the disappearance of tumor staining.

Under local anesthesia, the right femoral artery was accessed and a 5F-Cobra catheter (Terumo, Japan) was introduced. Tumor-feeding vessels were catheterized and embolized, including bronchial arteries, internal thoracic arteries, phrenic arteries. A 2.7-F microcatheter (Progreat, Terumo, Japan) was used for super-selection of all tumor-feeding arteries. Cisplatin or carboplatin was initially infused for patients with no previous platinum-based chemotherapy. Docetaxel was infused for patients receiving non-platinum-containing regimen. Gemcitabine (0.4–1.0 g) was pre-loaded with CalliSpheres beads for 30 min, and then mixed with iodixanol (ratio 1:1) as contrast developer before embolization. CalliSpheres beads were slowly injected into the tumor-feeding vessels under fluoroscopic guidance. One vial of CalliSpheres beads embolization was used for each patient, additional embolization was performed by using polyvinyl alcohol particles (Merit, American) or gelatin sponge particles if embolization is insufficient (Figure 2D; Figures 3C,D; Figures 4C,E).

The femoral artery was accessed after local anesthesia and a 5F-Cobra catheter (Terumo, Japan) was introduced. Tumor-feeding vessels were catheterized and a 2.7-F microcatheter (Progreat, Terumo, Japan) was used for super-selection. The dose of raltitrexed is calculated based on the Body Mass Index, and is generally 4 mg. Raltitrexed (4 mg) was pre-loaded into microspheres (CalliSpheres, Jiangsu Hengrui Medicine Co. Ltd., Jiangsu, China) for 30 min, and then mixed with iodixanol (ratio 1:1). A bottle of 100–300 μm or 300–500 μm raltitrexed-loaded microspheres was slowly injected into the tumor-feeding vessels. Polyvinyl alcohol particles (Merit, American) or gelatin sponge particles were used if one bottle of microspheres embolization was insufficient (Figs. 1CD, 2CE, 3BCE and 4BCE).